by Jon Rappoport May 24, 2017
The company is NewLink. The vaccine, or drug, depending on how it is defined, is called algenpantucel-L. A clinical trial of the drug recently failed to produce benefits in cancer patients, and the stock price of the company took a major dive.
A shareholder in NewLink, Rickey Ely, decided to sue.
His reasons are interesting, to say the least.
Clinical trials of new drugs seeking FDA approval go through four phases. The lawsuit states that phase 2 produced no encouraging results, violated standard protocol (there was no control group), and yet the company hyped the outcome of phase 2, and launched phase 3 only a few months after starting phase 2. Phase 3 shouldn’t have been initiated at all.
Owing to the company’s PR machine, shareholders were encouraged, but when phase 3 turned out to be a bust, the company’s stock price collapsed—thus…
View original post 175 more words
Health News Disclosure 